USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ANTICANCER, INC.
Address:
ANTICANCER, INC.
7917 OSTROW STREET
SAN DIEGO, CA
Phone:
N/A
URL:
N/A
EIN:
330074191
DUNS:
173844010
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,516,144.00 24
SBIR Phase II $5,538,487.00 9

Award List:

CELLULAR PARAMETERS OF DRUG SENSITIVITY IN HUMAN TUMORS IN VITRO

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$49,000.00
Agency:
HHS
Principal Investigator:
Peter H Stern , Principal Investigator
Abstract:
N/a

A METHIONINASE FOR METHIONINE-DEPENDENT CHEMOTHERAPY

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Peter H Stern Phd
Abstract:
N/a

CELLULAR PARAMETERS OF DRUG SENSITIVITY IN HUMAN TUMORS IN VITRO

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Peter H Stern , Principal Investigator
Abstract:
An important need in cancer chemotherapy is a highly predictive in vitro chemosensitivity assay. a major impediment to the development of such a test has been the lack of a suitable system for culturing human tumors in vitro so that they represent tumors in the in vivo state. to overcome this… More

COLON-CANCER-SPECIFIC GENES AS PROBES

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Due to an incomplete understanding of the disease, the prognosis of colon cancer, a high-incidence cancer in western countries, has not improved significantly. most of the studies in the molecular biology of colon cancer have focused on the study of a limited set of approximately 25-40genes, termed… More

A METHIONINASE FOR METHIONINE-DEPENDENT CHEMOTHERAPY

Award Year / Program / Phase:
1990 / SBIR / Phase II
Award Amount:
$486,774.00
Agency:
HHS
Principal Investigator:
Peter H Stern Phd
Abstract:
New approaches are necessary to improve chemotherapy of solid tumors. for this purpose, anticancer, inc. has taken advantage of the cancer-specific metabolic defect of methionine dependence, which causes many types of cancer cells to reversibly arrest late in the s/g2 phase of the cell cycle in… More

HISTOCULTURE OF SKIN FOR TOXICITY ASSAY

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Li, Lingna , Principal Investigator
Abstract:
There is an important need in the study of toxicology of topically-applied and environmental agents for an in vitro system to study their toxic effects on skin. the in vitro systems have the benefit of allowing study of a large variety of substances on an individual specimen. an in vitro system… More

ORTHOTOPIC HUMAN TUMOR IMPLANTS IN NUDE MICE

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Fu, Xinyu , Principal Investigator
Abstract:
Metastatic rates from subcutaneous xenografts in nude mice have been low possibly due to site of implantation. the approach is to use orthotopic onplanation of intact tissue specimens rather than cultured cell lines or dissociated tissue specimens. results have indicated a high take rate (success in… More

SCID MICE FOR IMMUNE THERAPY OF METASTATIC HUMAN CANCER

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,750.00
Agency:
HHS
Principal Investigator:
Xinyu Fu
Abstract:
We have recently developed in nude mice orthopedic metastasizing onplant models for colon, bladder, lung, head and neck, prostate, stomach, ovarian, pancreas and breast cancers. we will utilize severe combined immunodeficient (scid) mice to develop subsequend models for the development of… More

METAMOUSE FOR DIAGNOSTIC AND THERAPEUTIC TUMOR MARKERS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Xinyu Fu
Abstract:
A number of monoclonal antibodies (mabs) specific for tumor-associated antigens have been analyzed for immunolocalization and/or tumor-growth inhibition in athymic mice bearing subcutaneously transplanted human xenografts derived from tumor cell lines. although the subcutaneous-transplant nude-mouse… More

LIPOSOMES FOR DELIVERY OF DRUGS TO HAIR-FOLLICLE CELLS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Lingna Li
Abstract:
N/a

Phosphonium-Taxol Conjugates as Antitumor Drugs

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Xiaoen Wang
Abstract:
Taxol is a promising new cancer agent. We will determine whether phosphonium-ion conjugates of taxol would be more effective in a patient-like animal model. It has recently been demonstrated that taxol inhibits the metastatic spread of a PC-3 human prostate tumor cell subline in a SCID (severe… More

In Vitro Assays for Methionine-Dependent Chemotherapy

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Hui-yan Guo
Abstract:
We are developing a new tumor selective treatment termed antimethionine chemotherapy. Many tumor types have been shown to exhibit an absolute requirement for methionine in vitro in order to proliferate. Normal cells and tissues can utilize homocysteine in place of methionine in order to proliferate.… More

LIPOSOMES FOR DELIVERY OF DRUGS TO HAIR-FOLLICLE CELLS

Award Year / Program / Phase:
1996 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Lingna Li
Abstract:
There is a need to stimulate hair growth for various conditions of alopecia. it is asserted that to achieve hair growth stimulation, biologically active compounds must be delivered inside hair follicle cells, and that the optimal way to identify active compounds and methods of their delivery is to… More

Tumor implants to nude mice for cancer models

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$327,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

R-HOMOCYSTEINASE FOR HOMOCYSTEINE ASSAY

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Yuying Tan
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$219,420.00
Agency:
HHS
Principal Investigator:
Yuying Tan
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Yuying Tan
Abstract:
N/a

RHOMOCYSTEINASE FOR HOMOCYSTEINE ASSAY

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Yuying Tan
Abstract:
N/a

RHOMOCYSTEINASE FOR HOMOCYSTEINE ASSAY

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$463,300.00
Agency:
HHS
Principal Investigator:
Yuying Tan
Abstract:
N/a

GFP IMAGING FOR IN VIVO HIGH-THROUGHPUT DRUG SCREENING

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$250,000.00
Agency:
HHS
Principal Investigator:
Meng Yang
Abstract:
N/a

INHIBITORS OF 5ALPHA-REDUCTASE FOR ACNE THERAPY

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
Abstract:
This application addresses the need for selective non-toxic for acne. Excessive 5alpha-reductase activity is found in acne vulgaris as well as androgenic alopecia (male pattern baldness). Numerous side effects occur from current treatments of these diseases both of which originate in the… More

Orthotopic models of tumor angiogenesis and blood flow

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is a need for clinically relevant animal models of tumor angiogenesis and blood flow, two critical targets for current drug evaluation and development. Most models of angiogenesis and blood flow are either based on subcutaneous transplantation of tumors or… More

Dual-color tumor-host imaging models

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
Abstract:
Estimates of the hip joint centers (HJC) are usually based on predictions from anatomical landmarks and anthropometrical measures such as pelvic breadth. There is concern regarding the relevance of this approach in patients characterized by obesity or pelvic deformity. Recent investigations have… More

Discovery of novel fluorescent reporter genes

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The green fluorescent protein (GFP) from Aequorea victoria has been developed into a highly versatile reporter gene. Another family of fluorescent proteins, including Discosoma Red (DsRed), has been cloned from corals (4). This was followed by Anemonia asRed (5)… More

Enzyme therapy for hyperhomocysteinemia

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Numerous studies have demonstrated that homocysteine (HCY) is a major risk factor in heart disease and stroke. Recent studies have shown that lowering HCY levels with large doses of folate have reduced the incidence of cardiovascular disease. However, in… More

Therapeutic hair follicle-derived neurospheres

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The ready availability of pluripotent adult stem cells would have many important therapeutic applications. Our recent results suggest that the hair follicle is a promising source for such stem cells. Our recent discovery that the neural stem cell marker, nestin… More

Orthotopic models of tumor angiogenesis and blood flow

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$749,696.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is a need for clinically-relevant imageable animal models of tumor blood flow, intravascular cancer-cell trafficking and extravasation, critical targets for current drug evaluation and development. Most models of tumor cell trafficking and blood flow are… More

Dual-color tumor-host imaging models

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$751,568.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This Phase II application will further develop dual-color imageable tumor-host-interaction nude mouse models, developed in the Phase I application, to be used in Phase III to discover and evaluate new effective agents for stromal therapy, including angiogenesis.… More

Therapeutic hair follicle-derived neurospheres

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$749,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The facile availability of pluripotent adult stem cells would have many important therapeutic applications. Our recent results suggest that the hair follicle is a promising source for such stem cells. Our discovery that the neural stem cell marker nestin is… More

Imageable tumor-targeting bacteria

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$149,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this application is to develop imageable tumor-targeting bacteria that can cure tumors without progressive infection of the host. Previous experiments employed anaerobic microorganisms for cancer therapy but used a markedly different approach.… More

Targeted tumoricidal bacteria

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$149,799.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this application is to develop imageable tumor-targeting bacteria that can cure tumors without progressive infection of the host. Previous experiments by others employed anaerobic microorganisms for cancer t herapy. Target specificity appeared largely… More

Adenoviral GFP targeting of metastatic human tumors using multiple delivery route

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$149,575.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We are developing a new approach to image tumors by selectively targeting the tumors in vivo with a telomerase-specific replication-competent adenovirus expressing green fluorescent protein (GFP) (OBP-401). OBP-401 cont ains a replication cassette in which the… More

Targeted tumoricidal bacteria

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$761,149.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We have developed an effective bacterial cancer therapy strategy by targeting viable tumor tissue by using Salmonella typhimurium auxotrophs that we have generated which grow in viable as well as necrotic areas of tumor s. However, the auxotrophy severely… More